CA-14089/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1976	1
1980	4
1981	8
1982	12
1983	9
1984	3
1985	8
1986	4
1987	3
1988	1
1989	2
1990	4
1991	4
1992	5
1993	2
1994	4
1995	1
1996	3
1997	6
1999	1
2000	4
2001	3
2002	4
2003	3
2004	3
2005	2
2006	5
2007	7
2008	2
2009	2
2010	3
2015	1
2024	0

1

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Mitra AP, Datar RH, Cote RJ. Mitra AP, et al. J Clin Oncol. 2006 Dec 10;24(35):5552-64. doi: 10.1200/JCO.2006.08.2073. J Clin Oncol. 2006. PMID: 17158541 Review.

2

p53 and retinoblastoma pathways in bladder cancer.

Mitra AP, Birkhahn M, Cote RJ. Mitra AP, et al. World J Urol. 2007 Dec;25(6):563-71. doi: 10.1007/s00345-007-0197-0. Epub 2007 Aug 21. World J Urol. 2007. PMID: 17710407 Review.

3

Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States).

Cozen W, Peters R, Reichardt JK, Ng W, Felix JC, Wan P, Pike MC. Cozen W, et al. Cancer Causes Control. 2002 Mar;13(2):113-20. doi: 10.1023/a:1014384027523. Cancer Causes Control. 2002. PMID: 11936817

4

Molecular markers for bladder cancer: the road to a multimarker approach.

Birkhahn M, Mitra AP, Cote RJ. Birkhahn M, et al. Expert Rev Anticancer Ther. 2007 Dec;7(12):1717-27. doi: 10.1586/14737140.7.12.1717. Expert Rev Anticancer Ther. 2007. PMID: 18062746 Review.

5

The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer.

Gonzalgo ML, Datar RH, Schoenberg MP, Cote RJ. Gonzalgo ML, et al. Urol Oncol. 2007 May-Jun;25(3):228-35. doi: 10.1016/j.urolonc.2006.07.020. Urol Oncol. 2007. PMID: 17483020 Review.

6

Elevated levels of prolactin in nulliparous women.

Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC. Yu MC, et al. Br J Cancer. 1981 Jun;43(6):826-31. doi: 10.1038/bjc.1981.121. Br J Cancer. 1981. PMID: 7248160 Free PMC article.

7

Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.

Hong PS, Srigritsanapol A, Chan KK. Hong PS, et al. Drug Metab Dispos. 1991 Jan-Feb;19(1):1-7. Drug Metab Dispos. 1991. PMID: 1673381

8

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.

George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ. George B, et al. J Clin Oncol. 2007 Dec 1;25(34):5352-8. doi: 10.1200/JCO.2006.10.4125. J Clin Oncol. 2007. PMID: 18048815

9

Human amelogenins: sequences of "TRAP" molecules.

Fincham AG, Hu YY, Pavlova Z, Slavkin HC, Snead ML. Fincham AG, et al. Calcif Tissue Int. 1989 Oct;45(4):243-50. doi: 10.1007/BF02556044. Calcif Tissue Int. 1989. PMID: 2509010

10

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.

Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Weber J, et al. Cancer. 2003 Jan 1;97(1):186-200. doi: 10.1002/cncr.11045. Cancer. 2003. PMID: 12491520 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

123 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year